J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?

Johnson & Johnson (JNJ) shares have gained 17.7% over three months, adding $63 billion in market capitalization, supported by bullish technical indicators. The company reports modest growth in its Innovative Medicine segment (2.4% H1 2025) despite Stelara's patent loss and strong MedTech performance (6.1% Q2) driven by acquisitions, with expectations for accelerated growth from 2026 via pipeline and M&A. However, JNJ faces significant headwinds including a 38.6% decline in Stelara sales post-patent expiry, a projected $2 billion negative impact from Medicare Part D redesign, over 70,000 unresolved talc lawsuits, and potential pharma tariffs. Despite these challenges and a premium valuation of 15.51x forward earnings, JNJ's 2025/2026 EPS estimates have slightly risen, reflecting confidence in its strategic navigation.

Analysis

Johnson & Johnson has demonstrated significant market momentum, with its stock gaining 17.7% and adding approximately $63 billion in market capitalization over the past three months, supported by bullish technical indicators such as a "golden cross" in mid-July. This performance is underpinned by resilient fundamentals, as the Innovative Medicine segment grew sales by 2.4% in the first half of 2025 despite the loss of exclusivity for its blockbuster drug, Stelara. Management projects this unit will grow 5-7% annually from 2025 to 2030, driven by key products and a pipeline of ten potential drugs with peak sales estimates of $5 billion each. The MedTech segment also showed strength, with sales rising 6.1% operationally in the second quarter, boosted by recent acquisitions like Abiomed and Shockwave. However, the company faces substantial headwinds. Stelara sales plummeted 38.6% in the first half of 2025 due to biosimilar competition, and the Medicare Part D redesign is expected to create a negative sales impact of approximately $2 billion in 2025. Furthermore, significant uncertainty persists from over 70,000 unresolved talc lawsuits and potential pharmaceutical import tariffs. Despite a premium valuation, with a forward P/E of 15.51x above the industry average, consensus earnings estimates for 2025 and 2026 have seen a slight upward revision, indicating market confidence in the company's ability to navigate these challenges.

Key Decisions for Investors

• Investors should weigh the significant near-term headwinds, including the full impact of Stelara's patent cliff and a $2 billion revenue risk from Medicare policy, against the company's robust long-term growth outlook driven by its innovative pipeline and MedTech acquisitions.
• The unresolved litigation involving over 70,000 talc lawsuits represents a material financial overhang, and any adverse developments could significantly impact shareholder value, warranting close monitoring.
• Given the stock's recent 23.1% year-to-date appreciation and a valuation premium to its peers and historical average, initiating new positions may require careful consideration of entry points, particularly as near-term volatility from legal and regulatory news is likely.
• For existing long-term holders, the company's ability to deliver on its pipeline milestones and achieve its 2030 oncology sales target of over $50 billion will be critical to justifying the current valuation and offsetting the erosion of legacy product sales.